Most astute investors, in this market climate, prefer to concentrate on a Company's future potential instead of living in the past by waiting for and reading outdated SEC releases. In the case of CardioGenics, the questions raised are indicative of an inability to discover information by utilizing time tested investigative techniques. For an investor, using the proper due diligence, the questions raised would be insignificant.